top of page

No disclosure of irreversible effects, fertility impacts, or psychiatric outcomes

AHPRA Findings 5 and 6 (Audit Sections 3A, 4, 5) document critical omissions across three material domains: the clinic acknowledges high baseline psychiatric morbidity but omits evidence that needs often persist or increase post-treatment; provides no disclosure that some treatment effects are irreversible; and lists fertility preservation as an unavailable future service while failing to warn that hormone therapy itself may permanently impair fertility and sexual function.


These omissions create a misleading impression that medical transition is low-risk and reversible, when independent evidence shows otherwise.

Key evidence

The audit identified systematic omissions across four interconnected domains:
 

1. Mental health & psychiatric outcomes

What the website says:
Mental Health page acknowledges "high rates of trauma, PTSD, anxiety, depression, suicidality and other mental-health challenges" among clients.
 

What it omits:

  • Longitudinal evidence showing psychiatric service use often increases post-medical intervention (Ruuska 2026: 9.8% → 60.7% in feminising pathway; 21.6% → 54.5% in masculinising pathway)

  • Evidence that high baseline psychiatric morbidity may persist or worsen despite treatment

  • Low/very-low certainty evidence for mental health benefits (Cass 2024, York reviews 2024, US HHS 2025)

  • No disclosure that treatment is often sought for mental health reasons but evidence of mental health benefit is weak
     

2. Irreversibility of treatment effects

What the website says:
Lists "Gender Affirming Hormone Therapy" as current service.

What it omits:

  • Voice deepening (testosterone) is permanent

  • Breast development (oestrogen) is not fully reversible

  • Genital development changes may be irreversible

  • Sexual function changes may persist after stopping

  • Some effects are permanent regardless of treatment cessation

No disclosure anywhere that "trying" hormones may result in permanent changes.
 

3. Fertility impairment

What the website says:
Gender Affirmation page lists fertility preservation as "future unavailable service" described as "on-site consultation and support for fertility preservation before or during transition."
 

What it omits:

  • Hormone therapy itself may permanently impair fertility

  • Oestrogen may reduce sperm production; reversibility not guaranteed

  • Testosterone may affect ovulation and ovarian function; resumption of fertility uncertain

  • Fertility preservation must occur before treatment for pre-pubertal minors (but service unavailable)

  • Young people may lose reproductive capacity before preservation becomes available
     

Listing preservation as unavailable while offering hormones creates material disclosure gap: treatment that may eliminate fertility is available, but preservation is not.
 

4. Sexual function & development
What the website says:
Nothing. Complete silence.
 

What it omits:

  • Effects on libido, erectile function, orgasmic capacity

  • Impacts on genital development if started young

  • Sexual function changes may be irreversible or only partly reversible

  • Long-term sexual function data are sparse and uncertain

The legal issue

Section 133(1)(a) & (d): Misleading by omission + unreasonable expectations
These omissions are material because they affect:
 

Decision to pursue treatment:
Young people and families considering medical transition cannot assess whether:

  • Mental health is likely to improve (evidence is weak)

  • Changes can be reversed if they change their mind (some cannot)

  • They will retain reproductive capacity (may not)

  • Sexual function will be affected (likely but uncertain how)
     

Realistic outcome expectations:
The systematic omission of permanence, fertility impacts, and psychiatric outcome evidence creates unreasonable expectation that:
 

  • Treatment is reversible ("pause button" framing)

  • Mental health will improve (evidence doesn't support this)

  • Fertility preservation will be available when needed (it's not)

  • Sexual development won't be affected (it may be)
     

By presenting benefits while omitting irreversibility, fertility risks, and psychiatric evidence, the website misleads consumers about the fundamental nature of the pathway they're considering.

 

What the Evidence Actually Shows 

Psychiatric outcomes: Needs often persist or increase

Independent longitudinal evidence contradicts the assumption that mental health improves with medical treatment:
 

Ruuska 2026 (Finnish 10-year register study):
Psychiatric service use increased significantly post-medical gender reassignment:
 

  • Feminising pathway: 9.8% → 60.7%

  • Masculinising pathway: 21.6% → 54.5%

  • Needs remained 3–6× higher than matched controls regardless of medical intervention
     

Cass Review 2024, York reviews 2024, US HHS 2025:
All found low to very-low certainty evidence for mental health benefits. Short-term improvements reported in some observational studies, but causality uncertain and long-term benefits not established.
 

What this means:
High baseline psychiatric morbidity is not reliably resolved by medical treatment. In many cases, psychiatric needs intensify after intervention. Families deserve to know this before pursuing medical pathways for mental health reasons.

Irreversibility: Some changes are permanent

Independent evidence establishes that some treatment effects persist regardless of cessation:
 

Permanent with testosterone:

  • Voice deepening

  • Facial and body hair growth

  • Genital changes (clitoral growth)
     

Permanent or not fully reversible with oestrogen:

  • Breast development (surgical removal required to reverse)

  • Reduced testicular size
     

May persist after stopping:

  • Sexual function changes (libido, erectile function, orgasmic capacity)

  • Some fertility impairment
     

What this means:
"Trying" hormones is not a reversible experiment. Some changes are permanent from the first dose. Young people considering treatment need to understand they may be making irreversible decisions about their bodies.

Fertility: Window closes before preservation available

The temporal mismatch between hormone availability and preservation availability creates impossible situation:

​

Current services: Gender-affirming hormone therapy
Future unavailable service: Fertility preservation
 

The problem:

  • Hormone therapy may permanently impair fertility

  • Fertility preservation must occur before treatment begins (for pre-pubertal patients)

  • Listing preservation as unavailable while offering hormones means young people may lose reproductive capacity before preservation becomes accessible
     

Independent evidence:

  • Oestrogen reduces sperm production; resumption not guaranteed (de Nie 2023)

  • Testosterone affects ovulation; fertility recovery uncertain and variable

  • For pre-pubertal patients, fertility preservation may be physiologically impossible if treatment prevents reproductive maturation
     

What this means:
Young people may make irreversible reproductive decisions before they understand the implications or have preservation options available.

Download the Check-list

Want to know what questions gender clinics should be answering?

​

These check-lists document the specific information that should be disclosed before starting treatment — based on independent evidence reviews and informed consent standards.
 

                                 Puberty Blockers Check-list


                                 Masculinising Hormones (Testosterone) Check-list

                                 Feminising Hormones (Oestrogen) Check-list

                                 Surgery Referral Pathways Check-list
 

Print these and take them to your doctor. Every question deserves an answer.

Detail Evidence by Domain

Psychiatric outcomes - detailed evidence Ruuska et al. 2026 — Finnish nationwide register study (n=2,083 gender-referred adolescents + 16,643 matched controls, 1996–2019): Psychiatric morbidity markedly higher than controls both before (45.7% vs 15.0%) and ≥2 years after referral (61.7% vs 14.6%). Psychiatric service use increased significantly post-medical gender reassignment: • Feminising hormone pathway: 9.8% → 60.7% • Masculinising hormone pathway: 21.6% → 54.5% Adjusted hazard ratios remained 3–6× higher than controls regardless of medical intervention. Later cohorts (post-2010) showed greater psychiatric needs than earlier cohorts. Cass Review 2024: Systematic evidence review found low to very-low certainty evidence for mental health benefits of puberty blockers and cross-sex hormones. Recommended holistic assessment and caution against routine medical pathways. US HHS 2025: Umbrella review found very low certainty of long-term benefits; sparse and weak harms reporting; absence of detected harm ≠ evidence of safety. York/Archives of Disease in Childhood 2024: Two independent systematic reviews found no high-quality comparative studies; evidence is low/very low certainty for mental health, cognitive, fertility, sexual function, and cardiometabolic outcomes.

Irreversibility - what's permanent, what's not Permanent effects (testosterone): • Voice deepening - cannot be reversed without surgical intervention • Facial and body hair growth - persists after stopping (removal requires ongoing hair removal treatments) • Genital changes (clitoral growth) - permanent Permanent or not fully reversible (oestrogen): • Breast development - does not fully reverse; surgical removal required to restore pre-treatment chest appearance • Testicular size reduction — may be irreversible May persist (both): • Sexual function changes — libido, erectile function, orgasmic capacity may not fully recover • Fertility impairment — resumption not guaranteed; depends on duration, age, baseline fertility Timeline: Some changes are permanent from early in treatment. Voice deepening can begin within 3–6 months of testosterone. Breast development begins within 3–6 months of oestrogen. What "trying hormones" means: There is no fully reversible trial period. Permanent changes may occur before someone is certain about their decision.

Fertility impairment - evidence and uncertainty Oestrogen (feminising hormones): • Reduces sperm production • Small cohort study (de Nie 2023) showed spermatogenesis may return after cessation in some cases • Reversibility not guaranteed; depends on baseline fertility, duration of treatment, age, treatment regimen • Long-term fertility data limited Testosterone (masculinising hormones): • May affect ovulation and ovarian function • Some individuals may resume ovulation after stopping • Resumption not guaranteed; depends on age, duration, ovarian reserve • Robust comparative fertility studies limited; quantified incidence uncertain For pre-pubertal or early-pubertal patients: • Fertility preservation may be physiologically impossible if reproductive maturation hasn't occurred • Girls: egg retrieval requires reproductive system maturity • Boys: sperm production requires puberty to have progressed The temporal trap: If puberty blockers prevent maturation, and hormones are started before fertility preservation is possible, reproductive capacity may be permanently lost before preservation option ever existed.

Sexual function — sparse long-term data Known effects: • Reduced libido (both testosterone and oestrogen) • Erectile function changes (oestrogen) • Orgasmic function changes (both) • Genital development effects if started young Evidence quality: Very low — systematic reviews note sexual function outcomes are infrequently measured with standardised instruments in many cohorts. Long-term sexual function data are sparse. Reversibility: Uncertain — sexual function changes may be partly reversible after stopping, but some effects may persist. Long-term data insufficient to quantify persistence rates. Why it matters: Sexual development occurs during puberty. If treatment pauses or alters pubertal sexual development, long-term effects on adult sexual function are not well understood. The uncertainty itself is material to informed consent.

For Parents

What this means for you

Your child may be seeking treatment because they're distressed. But the evidence shows psychiatric needs often don't improve and may increase after treatment. Some treatment effects are permanent — voice, breast development, infertility. Fertility preservation isn't available while hormones are. You cannot give informed consent if you don't know that "trying" hormones may result in irreversible changes to your child's body and reproductive capacity. These aren't scare tactics — this is what the independent evidence shows.

For Mps

Policy & regulatory issue

Three critical omissions that undermine informed consent: (1) psychiatric evidence showing needs often persist or worsen,
(2) irreversibility of certain effects,
(3) fertility impairment while preservation unavailable. Each alone is material; together they constitute systematic misleading by omission. Regulatory action needed to require gender clinics disclose psychiatric outcome evidence, permanence of effects, and fertility risks with comparable prominence to benefit claims.

For Health Professionals

Clinical & professional standards issue

If referring patients to this clinic, ensure you independently provide:
(1) psychiatric outcome evidence (Ruuska 2026 showing increased needs post-treatment),
(2) irreversibility information (voice, breast development, fertility),
(3) fertility preservation timing (must occur before treatment; currently unavailable at this clinic). Professional responsibility requires ensuring patients understand what the clinic's website omits. The Informed Consent Standard requires material risk disclosure - the clinic's website doesn't meet it.

Related findings

These omissions connect to broader compliance failures:
 

  • Finding 1: Overall Impression - Benefit-oriented language throughout; no acknowledgement of irreversibility

  • Finding 2: Unqualified Claims - "Safe" claims without disclosure of permanent effects

  • Finding 3: Risk Disclosure - Zero mention of fertility or sexual function risks

  • Finding 4: Minors - Particularly material for young people who may not understand permanence

Copyright 2022 by (Active Watchful Waiting inc.)

  • LinkedIn
  • Twitter
  • YouTube
bottom of page